IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.273
AS - Asia 5.908
EU - Europa 5.497
SA - Sud America 1.660
AF - Africa 288
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 25.650
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.052
SG - Singapore 2.526
IT - Italia 2.084
CN - Cina 1.388
BR - Brasile 1.294
HK - Hong Kong 751
SE - Svezia 667
RU - Federazione Russa 527
DE - Germania 460
UA - Ucraina 448
FI - Finlandia 382
FR - Francia 381
VN - Vietnam 363
GB - Regno Unito 251
IN - India 186
BD - Bangladesh 145
AR - Argentina 129
CA - Canada 103
CI - Costa d'Avorio 97
ID - Indonesia 78
TR - Turchia 70
IQ - Iraq 65
MX - Messico 59
NL - Olanda 56
CO - Colombia 54
ZA - Sudafrica 53
EC - Ecuador 51
IE - Irlanda 47
PL - Polonia 43
SA - Arabia Saudita 42
JP - Giappone 41
PK - Pakistan 41
VE - Venezuela 41
ES - Italia 34
MA - Marocco 33
CL - Cile 28
UZ - Uzbekistan 28
BE - Belgio 25
PY - Paraguay 25
TN - Tunisia 23
JO - Giordania 22
CZ - Repubblica Ceca 21
JM - Giamaica 21
PE - Perù 21
EG - Egitto 19
PH - Filippine 18
MY - Malesia 14
AT - Austria 13
AU - Australia 13
ET - Etiopia 13
AE - Emirati Arabi Uniti 12
AZ - Azerbaigian 11
KE - Kenya 11
LT - Lituania 11
IL - Israele 10
IR - Iran 10
KR - Corea 9
NP - Nepal 9
UY - Uruguay 9
CR - Costa Rica 8
KZ - Kazakistan 8
TH - Thailandia 8
BO - Bolivia 7
GT - Guatemala 7
OM - Oman 7
PS - Palestinian Territory 7
HN - Honduras 6
SN - Senegal 6
TW - Taiwan 6
BY - Bielorussia 5
EU - Europa 5
XK - ???statistics.table.value.countryCode.XK??? 5
AL - Albania 4
AO - Angola 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
LB - Libano 4
LY - Libia 4
MD - Moldavia 4
MU - Mauritius 4
RO - Romania 4
BN - Brunei Darussalam 3
GE - Georgia 3
HU - Ungheria 3
MN - Mongolia 3
MT - Malta 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TG - Togo 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
BJ - Benin 2
BS - Bahamas 2
CY - Cipro 2
DK - Danimarca 2
EE - Estonia 2
GA - Gabon 2
Totale 25.608
Salva come PNG Salva come JPEG
Città #
Singapore 1.321
Ashburn 1.131
Jacksonville 1.021
Chandler 1.013
Woodbridge 891
Fairfield 816
Hong Kong 730
San Jose 723
Milan 701
Houston 530
Nyköping 468
Ann Arbor 454
Cambridge 426
Seattle 332
Beijing 323
Wilmington 297
Roxbury 255
Lawrence 241
Nanjing 239
Rome 239
Lauterbourg 237
New York 210
Boardman 188
Los Angeles 171
Dallas 160
Des Moines 160
Bari 149
Helsinki 128
Ho Chi Minh City 124
Inglewood 106
Abidjan 96
São Paulo 95
Columbus 94
Princeton 89
Santa Clara 87
Brooklyn 82
Buffalo 75
Shenyang 72
Hanoi 71
Hebei 66
Florence 59
London 59
Council Bluffs 57
San Diego 56
Jiaxing 52
Dearborn 51
Turin 49
Dublin 45
Figino 44
Munich 44
Nanchang 44
Changsha 41
Moscow 39
Rio de Janeiro 38
Falkenstein 37
Nuremberg 37
Tianjin 37
Jakarta 36
Paris 36
Montreal 34
Guangzhou 33
Tokyo 33
Baghdad 32
Frankfurt am Main 32
Orem 32
Johannesburg 31
Phoenix 31
Warsaw 30
Pune 28
Toronto 28
Chennai 27
Chicago 27
Naples 27
Belo Horizonte 26
Tashkent 26
Turku 26
Atlanta 25
Brasília 25
Curitiba 25
Brussels 24
San Francisco 24
Dhaka 22
Redwood City 22
Medellín 21
The Dalles 21
Denver 20
Washington 19
Istanbul 18
Jinan 18
Amsterdam 17
Manchester 17
Quito 17
Campinas 16
Noicattaro 16
Salvador 16
Shanghai 16
Amman 15
Bologna 15
Guayaquil 15
New Delhi 15
Totale 16.434
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 214
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 206
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 200
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 191
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 189
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 188
Non-treatment-related chronic myeloid leukemia as a second malignancy 175
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 170
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 169
TRAIL effect on osteoclast formation in physiological and pathological conditions 167
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 162
Amyloid in bone marrow smears of patients affected by multiple myeloma 159
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 154
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 152
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 152
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 152
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 151
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 151
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 149
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 146
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 144
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 143
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 142
A rare case of IgM-Multiple Myeloma 141
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 139
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 138
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 138
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 137
Autoimmune Myelofibrosis: report of three cases and review of the literature 137
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 137
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 133
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 133
Ibridizzazione in situ non isotopica. Attualità e prospettive 133
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 133
A weekly infusion of bortezomib reduces peripheral neuropathy 133
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 132
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 132
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 131
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 131
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 130
Another link between bone and immune system: LIGHT 129
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 129
Acute tubular necrosis in the hemlock poisoning 126
Takayasu’s arteritis: a cell mediated large vessel vasculitis 126
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 126
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 126
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 125
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 125
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 124
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 123
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 123
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 122
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 121
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 121
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 120
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 118
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 118
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 116
Myeloma cells suppress osteoblasts through sclerostin secretion 116
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 115
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 115
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 115
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 115
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 114
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 114
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 114
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 114
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 114
The Role of LIGHT in Multiple Myeloma-Bone Disease 113
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 113
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 111
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 111
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 111
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 110
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 110
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 110
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 110
What Is New in the Treatment of Smoldering Multiple Myeloma? 109
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 108
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 108
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 107
Bone marrow angiogenesis in autoimmune myelofibrosis 107
LIGHT: another link between bone and immune system 107
Chirurgia degli aneurismi dei tronchi sovraaortici 106
DCR3 involvement in multiple myeloma bone disease 106
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 105
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 105
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 104
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 104
The role of the Wnt-signaling antagonist Sclerostin in the development of osteolytic lesions in multiple myeloma 102
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 102
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP) 102
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 101
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 101
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 101
Circulating levels of cathepsin-k in multiple myeloma patients 101
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 101
Anemia emolitica autoimmune sviluppata durante il trattamento di epatite cronica C con interferone-alfa 100
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 100
Kidney damage by ingestion of ethylene glicol 100
Totale 12.864
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.696
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.696
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.783 78 253 7 128 54 77 73 96 125 79 312 501
2022/20232.644 379 230 111 271 344 374 41 300 494 16 45 39
2023/20241.331 200 212 73 66 96 238 65 69 8 55 101 148
2024/20254.071 114 55 402 140 110 365 310 344 181 187 621 1.242
2025/20268.925 1.179 363 574 969 857 522 1.091 258 870 836 260 1.146
2026/2027313 313 0 0 0 0 0 0 0 0 0 0 0
Totale 26.026